MiMedx Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
MiMedx Group has been growing earnings at an average annual rate of 57.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 3.6% per year. MiMedx Group's return on equity is 47.4%, and it has net margins of 23.2%.
Anahtar bilgiler
57.6%
Kazanç büyüme oranı
56.0%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 3.6% |
| Özkaynak getirisi | 47.4% |
| Net Marj | 23.2% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Gelir ve Gider Dağılımı
MiMedx Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 343 | 79 | 210 | 11 |
| 30 Jun 24 | 340 | 79 | 209 | 11 |
| 31 Mar 24 | 335 | 68 | 216 | 12 |
| 31 Dec 23 | 321 | 56 | 216 | 13 |
| 30 Sep 23 | 309 | 19 | 215 | 6 |
| 30 Jun 23 | 295 | 2 | 219 | 8 |
| 31 Mar 23 | 281 | -18 | 225 | 10 |
| 31 Dec 22 | 268 | -27 | 221 | 13 |
| 30 Sep 22 | 261 | -34 | 216 | 22 |
| 30 Jun 22 | 256 | -28 | 209 | 20 |
| 31 Mar 22 | 258 | -19 | 202 | 19 |
| 31 Dec 21 | 242 | -18 | 199 | 10 |
| 30 Sep 21 | 260 | -35 | 223 | 16 |
| 30 Jun 21 | 261 | -83 | 233 | 15 |
| 31 Mar 21 | 246 | -88 | 231 | 13 |
| 31 Dec 20 | 248 | -83 | 240 | 12 |
| 30 Sep 20 | 256 | -73 | 212 | 11 |
| 30 Jun 20 | 281 | -8 | 210 | 10 |
| 31 Mar 20 | 294 | -17 | 233 | 11 |
| 31 Dec 19 | 299 | -26 | 265 | 11 |
| 30 Sep 19 | 315 | -54 | 270 | 13 |
| 30 Jun 19 | 314 | -67 | 287 | 14 |
| 31 Mar 19 | 342 | -48 | 295 | 15 |
| 31 Dec 18 | 359 | -30 | 295 | 16 |
| 30 Sep 18 | 354 | 41 | 275 | 15 |
| 30 Jun 18 | 352 | 59 | 260 | 16 |
| 31 Mar 18 | 333 | 65 | 235 | 17 |
| 31 Dec 17 | 321 | 65 | 220 | 18 |
| 30 Sep 17 | 303 | 35 | 216 | 18 |
| 30 Jun 17 | 283 | 21 | 205 | 15 |
| 31 Mar 17 | 264 | 15 | 192 | 14 |
| 31 Dec 16 | 222 | 0 | 172 | 14 |
| 30 Sep 16 | 227 | 20 | 168 | 11 |
| 30 Jun 16 | 212 | 23 | 154 | 10 |
| 31 Mar 16 | 200 | 27 | 144 | 9 |
| 31 Dec 15 | 187 | 29 | 133 | 8 |
| 30 Sep 15 | 175 | 20 | 126 | 8 |
| 30 Jun 15 | 160 | 17 | 115 | 8 |
| 31 Mar 15 | 139 | 11 | 104 | 7 |
| 31 Dec 14 | 118 | 6 | 90 | 7 |
| 30 Sep 14 | 97 | 1 | 75 | 7 |
| 30 Jun 14 | 79 | -3 | 64 | 6 |
| 31 Mar 14 | 67 | -3 | 54 | 5 |
| 31 Dec 13 | 59 | -4 | 46 | 5 |
Kaliteli Kazançlar: MDXG has a high level of non-cash earnings.
Büyüyen Kar Marjı: MDXG's current net profit margins (23.2%) are higher than last year (6.2%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MDXG has become profitable over the past 5 years, growing earnings by 57.6% per year.
Büyüme Hızlandırma: MDXG's earnings growth over the past year (315.6%) exceeds its 5-year average (57.6% per year).
Kazançlar vs. Sektör: MDXG earnings growth over the past year (315.6%) exceeded the Biotechs industry -2.3%.
Özkaynak Getirisi
Yüksek ROE: MDXG's Return on Equity (47.4%) is considered outstanding.